Foong-Yen Lim, MD, a pediatric and fetal surgeon, leads the Fetal Team as the Surgical Director of the Cincinnati Fetal Center (CFC). He has performed more than 500 fetoscopic procedures and various open fetal surgeries at CFC. Besides his leadership role locally, he currently serves on the Fetal Diagnosis and Treatment Committee of the American Pediatric Surgical Association; and Board of Directors of the North American Fetal Therapy (NAFTNet). He also served as the Program Director of the 30th Annual International Fetal Medicine and Surgery Society (IFMSS) Conference.
Dr. Lim continues to expand his expertise in Pediatric General and Thoracic Surgery with an emphasis on congenital diaphragmatic hernia (CDH); congenital lung lesions such as congenital pulmonary airway malformation (CPAM); Bladder Outlet Obstruction (BOO); and bronchopulmonary sequestration (BPS); congenital high airway obstruction syndrome (CHAOS); and congenital tumors including giant cervical teratoma, and sacrococcygeal teratoma. In addition to serving as one of the attending physicians on the CDH Team that is dedicated to the care and management of all CDH patients, he is leading the clinical and research projects related to CDH and congenital lung lesions at Cincinnati.
Dr. Lim leads the Cincinnati Fetal Center Perinatal Research Group in clinical research with currently over thirty active IRB protocols. Together with the staff in Cincinnati Fetal Center, we are building a comprehensive data base for all of our patients to facilitate outcomes report and study. At Cincinnati Children’s, Dr. Lim collaborates with physicians and researchers at the Perinatal Institute, The Heart Institute, Division of Pulmonary Biology, Division of Radiology, Division of Otolaryngology, Division of Anesthesia, Division of Urology, and the Division of Pediatric General and Thoracic Surgery in various projects. The Cincinnati Fetal Center is also collaborating with physicians and researchers at the University Hospital and Good Samaritan Hospital in various projects. We also have robust involvement in multicenter trials, registries and projects such as International Stage I TTTS Trial, International Prenatal Tracheal Occlusion Trial for Severe CDH, DHREAMS (Diaphragmatic Hernia Research & Exploration; Advancing Molecular Science) study (NIH grant HD057036), International CDH Registry, North America registry for pregnancies complicated by prenatally diagnosed lower urinary tract obstruction (LUTO) with normal amniotic fluid volume, and NAFTNet-sponsor projects including “Natural history of Stage I Twin-Twin Transfusion Syndrome” and “Delivery indications for TTTS after laser ablation”; just to name a few.
Innovation of prenatal diagnosis and in utero treatment are the mainstay of the Lim lab. The ability to diagnose congenital conditions prior to birth has led to an opportunity to understand the natural history of these processes and provide antenatal therapy to prevent devastating morbidities and even death. While much of our focus is on risk stratification using prenatal evaluations and the development of prognostic indicators, we are also actively investigating the role of prenatal biomarkers that may provide insight into the development and progression of these fetal anomalies. The advancement and innovation of operative techniques can then be performed in animal models with translation into patient use.